We can’t show the full text here under this license. Use the link below to read it at the source.
Achieving the composite endpoint of glycated haemoglobin AWARD programme
Meeting blood sugar, weight, and low blood sugar goals with once-weekly dulaglutide in the AWARD program
AI simplified
Abstract
At 26 weeks, 37-58% of patients on dulaglutide 1.5 mg achieved the of <7.0%, no weight gain, and no hypoglycaemia.
- Dulaglutide 1.5 mg led to significantly higher odds of reaching the composite endpoint compared to metformin, sitagliptin, exenatide twice daily, and insulin glargine.
- Patients on dulaglutide 0.75 mg also demonstrated significantly higher odds of achieving the composite endpoint compared to sitagliptin and insulin glargine.
- No significant difference in the composite endpoint achievement was observed between dulaglutide 1.5 mg and liraglutide 1.8 mg.
AI simplified
Key numbers
1.5
Higher Odds of Achieving Endpoint with Dulaglutide 1.5 mg
Odds ratio for dulaglutide 1.5 mg vs. metformin
37–58%
Achievement Rate
Percentage of patients reaching <7.0%, no weight gain, no hypoglycaemia
27–49%
Achievement Rate for Dulaglutide 0.75 mg
Percentage of patients achieving the endpoint with dulaglutide 0.75 mg